Nexstim is committed to exploiting the commercial opportunity for its proprietary Navigated Brain Therapy (NBT) system in the rapidly growing depression market. The negative E-FIT stroke trial has closed the door on pursuit of stroke rehabilitation, necessitating a shift in strategy and resources towards commercialisation of NBT in major depressive disorder (MDD) in the US and Europe. First installations have occurred in multiple sites in the US, Europe and Asia, with the strategy to support further roll out across the US being advanced. We have revisited our forecasts and valuation to reflect Nexstim’s depression-led strategy, and now value the company at €35.9m, or €0.37/share (€0.34/share diluted).
11 Oct 2018
Navigating the opportunity in depression
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Navigating the opportunity in depression
Nexstim is committed to exploiting the commercial opportunity for its proprietary Navigated Brain Therapy (NBT) system in the rapidly growing depression market. The negative E-FIT stroke trial has closed the door on pursuit of stroke rehabilitation, necessitating a shift in strategy and resources towards commercialisation of NBT in major depressive disorder (MDD) in the US and Europe. First installations have occurred in multiple sites in the US, Europe and Asia, with the strategy to support further roll out across the US being advanced. We have revisited our forecasts and valuation to reflect Nexstim’s depression-led strategy, and now value the company at €35.9m, or €0.37/share (€0.34/share diluted).